NeuroBytes: A New Era In IDH-Mutant Grade 2 Gliomas: Utilizing a Targeted Therapy
Course Description
The presence of isocitrate dehydrogenase mutations are an important diagnostic feature of low-grade gliomas. The aim of this video is to explain why the IDH mutation is so important in both the diagnosis and biology of gliomas. This video also reviews the INDIGO trial, which showed that use of IDH-inhibitor vorasidenib in patients with IDH-mutated gliomas resulted in significant improvement in progression-free survival and “time to next treatment.”
Learning Objectives
As a result of this video the learner will be able to:
- Explain the significance of IDH mutations in the diagnosis and management of low-grade gliomas and describe the impact of vorasidenib in understanding and treating IDH-mutant gliomas grade II gliomas.
Date of Release
August 25, 2023
Confidentiality of Data
All material © American Academy of Neurology Institute unless otherwise indicated. All rights reserved. See complete
Terms of Use.
Faculty & Disclosures
NUPUR LALA, MD
Fellow in Neuro-Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
*Dr. Lala has nothing to disclose.
Fellow in Neuro-Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
*Dr. Lala has nothing to disclose.
ALEXANDRA GEWIRTZ, MD
Fellow in Neuro-Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
*Dr. Gewirtz has nothing to disclose.
Editor
RACHNA MALANI, MD
Assistant Professor of Neurosurgery
Huntsman Cancer Institue, University of Utah
Salt Lake City, UT
*Dr. Malani has nothing to disclose.
Reviewer
ADAM QUICK, MD
Associate Professor of Neurology
The Ohio State University Wexner Medical Center
Columbus, OH
*Dr. Quick has nothing to disclose.
Voiceover Artist
ZACHARY N. LONDON, MD, FAAN
Professor of Neurology
University of Michigan
Ann Arbor, MI
*Dr. London has nothing to disclose.
NeuroBytes Staff
Xiaoyu Sun, Associate Director, eLearning
Minneapolis, MN
*Ms. Sun has nothing to disclose.
Robert Rook, Manager, eLearning
Minneapolis, MN
*Mr. Rook has nothing to disclose.
Sulia Altenberg, eLearning Coordinator
Minneapolis, MN
*Ms. Altenberg has nothing to disclose.
*Relationship Disclosure